---
title: "Annexon grants new hires options for 287,500 shares at $5.29 each"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296140990.md"
description: "Annexon granted stock options for 287,500 shares to three new non-executive employees under its 2022 inducement plan. The options have a 10-year term with an exercise price of $5.29 per share, based on the August 14 closing price. Vesting occurs over four years, with 25% vesting on the first anniversary and the remainder monthly thereafter, subject to continued service."
datetime: "2026-08-17T20:06:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296140990.md)
  - [en](https://longbridge.com/en/news/296140990.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296140990.md)
generator: "portal-rs"
---

# Annexon grants new hires options for 287,500 shares at $5.29 each

-   Annexon granted stock options covering 287,500 shares to three new non-executive employees under its 2022 inducement plan. \* Options carry a 10-year term with an exercise price of $5.29 per share, set at the Aug. 14 closing price. \* Vesting runs over four years: 25% on the first anniversary, then monthly in equal installments, subject to continued service. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608171605PRIMZONEFULLFEED9810836) on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ANNX.US](https://longbridge.com/en/quote/ANNX.US.md)

## Related News & Research

- [Annexin expands NEXUS trial to allow anti-VEGF loading dose before vanexin in RVO patients](https://longbridge.com/en/news/296573642.md)
- [Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Rating of "Hold" from Analysts](https://longbridge.com/en/news/296803920.md)
- [13:51 ETWingspan Launches Employee Payroll Beta to Manage W-2 and 1099 Workers in One Platform](https://longbridge.com/en/news/296524030.md)
- [PharmAla Biotech says USPTO grants US patent for enantioselective MDMA, MBDB processes](https://longbridge.com/en/news/296608164.md)
- [AI Is Great at Generating Trading Ideas and Terrible at Knowing Which Ones Survive](https://longbridge.com/en/news/296527428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**